Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

11.70
+0.60005.41%
Post-market: 11.700.00000.00%16:10 EDT
Volume:1.04M
Turnover:12.10M
Market Cap:1.17B
PE:-7.96
High:11.99
Open:11.30
Low:11.29
Close:11.10
52wk High:14.93
52wk Low:3.90
Shares:100.36M
Float Shares:86.55M
Volume Ratio:0.60
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4700
EPS(LYR):-1.4747
ROE:-41.27%
ROA:-26.17%
PB:3.05
PE(LYR):-7.93

Loading ...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 08, 2025

Oric Pharmaceuticals Publishes Promising Data on Brain-Penetrant EGFR Inhibitor Enozertinib for NSCLC

Reuters
·
Nov 07, 2025

Oric Pharmaceuticals to Join Jefferies London Healthcare Conference

Reuters
·
Nov 05, 2025

Oric Pharmaceuticals’ Promising Study on ORIC-944 for Metastatic Prostate Cancer

TIPRANKS
·
Oct 28, 2025

Oric Pharmaceuticals Advances in NSCLC Treatment with Phase 1b Study

TIPRANKS
·
Oct 28, 2025

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

GlobeNewswire
·
Oct 27, 2025

Can Analyst Conviction in ORIC (ORIC) Data Shift Its Competitive Position in Prostate Cancer Therapy?

Simply Wall St.
·
Oct 18, 2025

ORIC Pharmaceuticals: Promising Oncology Developments and Strategic Trials Support Buy Rating

TIPRANKS
·
Oct 17, 2025

Why ORIC Pharmaceuticals (ORIC) Is Up 21.9% After Multiple Analyst Upgrades and CTO Appointment

Simply Wall St.
·
Oct 09, 2025

Oric Pharmaceuticals CEO Jacob Chacko Reports Sale of Common Shares

Reuters
·
Oct 09, 2025

Oric Pharmaceuticals CEO and President Jacob Chacko Reports Sale of Common Shares

Reuters
·
Oct 03, 2025

Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Sep 26, 2025

Oric Pharmaceuticals CEO Jacob Chacko Reports Sale of Common Shares

Reuters
·
Sep 25, 2025